Patients aged @ years or older with advanced gastric or gastro-oesophageal junction adenocarcinoma and disease progression on or within @ months after first-line chemotherapy ( platinum plus fluoropyrimidine with or without an anthracycline ) were randomly assigned with a centralised interactive voice or web-response system in a @:@ ratio to receive ramucirumab @ mg/kg or placebo intravenously on days @ and @ , plus paclitaxel @ mg/m ( @ ) intravenously on days @ , @ , and @ of a @-day cycle .